Sanae Sasaki1, Tyson H Holmes2, Randy A Albrecht3, Adolfo García-Sastre4, Cornelia L Dekker5, Xiao-Song He6, Harry B Greenberg7. 1. Department of Microbiology and Immunology VA Palo Alto Health Care System, California. 2. Department of Psychiatry and Behavioral Sciences. 3. Department of Microbiology Global Health and Emerging Pathogens Institute. 4. Department of Microbiology Global Health and Emerging Pathogens Institute Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Department of Pediatrics. 6. Department of Medicine, Stanford University School of Medicine, Stanford VA Palo Alto Health Care System, California. 7. Department of Microbiology and Immunology Department of Medicine, Stanford University School of Medicine, Stanford VA Palo Alto Health Care System, California.
Abstract
BACKGROUND: The immunological bases for the efficacies of the 2 currently licensed influenza vaccines, live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV), are not fully understood. The goal of this study was to identify specific B-cell responses correlated with the known efficacies of these 2 vaccines. METHODS: We compared the B-cell and antibody responses after immunization with 2010/2011 IIV or LAIV in young adults, focusing on peripheral plasmablasts 6-8 days after vaccination. RESULTS: The quantities of vaccine-specific plasmablasts and plasmablast-derived polyclonal antibodies (PPAbs) in IIV recipients were significantly higher than those in LAIV recipients. No significant difference was detected in the avidity of vaccine-specific PPAbs between the 2 vaccine groups. Proportionally, LAIV induced a greater vaccine-specific immunoglobulin A plasmablast response, as well as a greater plasmablast response to the conserved influenza nuclear protein, than IIV. The cross-reactive plasmablast response to heterovariant strains, as indicated by the relative levels of cross-reactive plasmablasts and the cross-reactive PPAb binding reactivity, was also greater in the LAIV group. CONCLUSIONS: Distinct quantitative and qualitative patterns of plasmablast responses were induced by LAIV and IIV in young adults; a proportionally greater cross-reactive response was induced by LAIV.
RCT Entities:
BACKGROUND: The immunological bases for the efficacies of the 2 currently licensed influenza vaccines, live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV), are not fully understood. The goal of this study was to identify specific B-cell responses correlated with the known efficacies of these 2 vaccines. METHODS: We compared the B-cell and antibody responses after immunization with 2010/2011 IIV or LAIV in young adults, focusing on peripheral plasmablasts 6-8 days after vaccination. RESULTS: The quantities of vaccine-specific plasmablasts and plasmablast-derived polyclonal antibodies (PPAbs) in IIV recipients were significantly higher than those in LAIV recipients. No significant difference was detected in the avidity of vaccine-specific PPAbs between the 2 vaccine groups. Proportionally, LAIV induced a greater vaccine-specific immunoglobulin A plasmablast response, as well as a greater plasmablast response to the conserved influenza nuclear protein, than IIV. The cross-reactive plasmablast response to heterovariant strains, as indicated by the relative levels of cross-reactive plasmablasts and the cross-reactive PPAb binding reactivity, was also greater in the LAIV group. CONCLUSIONS: Distinct quantitative and qualitative patterns of plasmablast responses were induced by LAIV and IIV in young adults; a proportionally greater cross-reactive response was induced by LAIV.
Authors: R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff Journal: J Infect Dis Date: 2000-03 Impact factor: 5.226
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: F K Lee; A J Nahmias; T Spira; H Keyserling; S Lowery; C Reimer; C Black; B Stoll; C Czerkinsky Journal: J Clin Immunol Date: 1991-07 Impact factor: 8.317
Authors: Xiao-Song He; Sanae Sasaki; Jane Baer; Surender Khurana; Hana Golding; John J Treanor; David J Topham; Mark Y Sangster; Hong Jin; Cornelia L Dekker; Kanta Subbarao; Harry B Greenberg Journal: J Infect Dis Date: 2012-10-29 Impact factor: 5.226
Authors: Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg Journal: PLoS One Date: 2008-08-20 Impact factor: 3.240
Authors: Mrinmoy Sanyal; Tyson H Holmes; Holden T Maecker; Randy A Albrecht; Cornelia L Dekker; Xiao-Song He; Harry B Greenberg Journal: J Infect Dis Date: 2019-04-19 Impact factor: 5.226
Authors: Xiao-Song He; Tyson H Holmes; Mrinmoy Sanyal; Randy A Albrecht; Adolfo García-Sastre; Cornelia L Dekker; Mark M Davis; Harry B Greenberg Journal: J Infect Dis Date: 2014-10-21 Impact factor: 5.226